Evidence Hub

LED red light therapy for relief of primary dysmenorrhea: An open, single-group target value clinical trial

Yi B, Wang D, Wei L, He J, Yu Q, Wu L, Wang Y, Wang Y et al.

PloS one, 2026

119 participants

Abstract

Objective: To evaluate the efficacy and safety of LED red light therapy in alleviating primary dysmenorrhea.

Methods: A total of 119 patients with primary dysmenorrhea were enrolled in 2022. The intervention was LED red light therapy administered 7 days before menstruation. Clinical outcomes were assessed after three menstrual cycles.

Results: After three cycles of treatment, the mean reduction rate in the Visual Analog Scale (VAS) score was 63.62%. The overall effective rate of the device was 98.32%. The total score of the COX Menstrual Symptom Scale decreased by 72.93%, with specific reductions of 72.55% in symptom severity and 73.26% in pain duration. No severe adverse events were reported during the trial. Only one adverse event (0.84%) was considered device-related.

Conclusion: LED red light therapy is safe and effective for the treatment of primary dysmenorrhea.

Trial registration: ChiCTR2600116460.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 119 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free